contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


orion-corporations-financial-reporting-and-annual-general-meeting-in-2025

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Orion operates in the pharmaceutical industry. The company conducts research and development of human and veterinary drugs, where the main focus is on diseases that affect the nervous system, as well as oncology and respiratory diseases. Today, the company's products are found on a global level, with the largest presence in the Nordic region and the rest of Europe. The company's head office is located in Espoo, Finland.

Antti has made a new company report on Orion  We raise our earnings estimates for Orion based on the outlook for Nubeqa, the company’s key earnings growth driver. Bayer, responsible for the sales and marketing of the best-in-class (AR inhibitor) prostate cancer drug, recently provided higher sales guidance for the drug than our estimates. Nubeqa’s market share gains appear to be continuing strongly. Future growth is also supported by new studies to be published in 2027 and 2028, which could further expand Nubeqa’s use. We raise our target price to 80 euros (previously 75€). We upgrade our recommendation to Buy (previously Accumulate) based on the attractive expected return.                   Inderes              Orion: Bayerin ohjeistus kertoo Nubeqan vahvuudesta - Inderes    Eturauhassyöpäläkkeen voittokulku jatkuu.

Thanks. It’s probably already been mentioned that Nordea has the same €75 target price, issued previously.

https://www.marketscreener.com/news/danske-bank-upgrades-orion-to-buy-hold-sets-price-target-at-75-euros-bn-ce7e5fdede8af721

Interesting information, the collaboration between Thestra and Orion. The target cancer is a very distressing disease; HNSCC causes great suffering. Head and neck squamous cell carcinoma (HNSCC) can form in the squamous epithelial layers of the oral cavity, larynx, nasopharynx, and oropharynx, from which it can invade and eventually metastasize. It is the eighth most common cancer in the world, and its incidence is expected to grow by 52% by 2045. Those affected by this type of tumor have an average five-year mortality rate of 50%, and survivors have the second-highest suicide rate of all cancers.

Turku-based Thestra finds a partner in Orion to support its unique invention Despite decades of research, there have been no targeted treatments for head and neck cancer. A medical startup has invented a method that ensures an accurate diagnosis of the cancer.                    ts.fi – 17 Feb 26              Turkulainen Thestra sai Orionista kumppanin ainutlaatuisen keksintönsä tueksi    Pään ja kaulan syöpään ei vuosikymmenten tutkimustuloksesta huolimatta ole ollut olemassa kohdennettuja hoitoja. Lääkätieteen start-up -firma keksi menetelmän, jolla syövän tarkka diagnoosi varmistuu.

And then potentially destroy Orion’s shareholder value in the process. As an Orion shareholder (I don’t own Faron), I do not support such a scenario at all. Deals can be made for interesting drug candidates, if there is potential. On the other hand, if Faron’s performance continues at this level, those assets could be acquired cheaply at some point—if there would even be any sense in that. And if Faron stays afloat, those who believe in it can certainly continue funding it as an independent company. Drug development is arduous and risky; I trust Orion’s experience in this.

Considering the precarious situation Faron has found itself in, perhaps the possibility of merging it with Orion should be seriously explored. Although Orion might not yet be considered a true Big Pharma (BP) company, a merger with Faron would not be an overwhelming risk for it. Perhaps a couple of million B-shares would be needed for a share swap, which is only just under 1.5 percent of Orion’s share capital, so it would likely hardly weigh on the stock price. It might even raise it. Orion would get more, at least somewhat promising, new candidates for its research pipeline. The EU would probably take an encouraging view of such a solution, and it would also be an interesting step for the development of the Finnish pharmaceutical industry.

Orion

ORION CORPORATION STOCK EXCHANGE RELEASE – FINANCIAL CALENDAR 8 AUGUST 2024 at 9.45 EEST Orion Corporation’s financial reporting and Annual General Meeting in 2025 Orion Corporation will publish...

ORION CORPORATION STOCK EXCHANGE RELEASE – FINANCIAL CALENDAR 8 AUGUST 2024 at 9.45 EEST&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Orion Corporation’s financial reporting and Annual General Meeting in 2025 Orion Corporation will publish its Financial Statement&nbsp;Release 2024 on Tuesday, 25 February 2025. The publication dates of the Interim Reports and the Half-Year Financial Report in 2025 are as follows: <table style="border-collapse: collapse; border-collapse:collapse ;"><tbody><tr><td style="width:321px;;vertical-align: top ;"> Interim Report January-March 2025 </td><td style="width:321px;;vertical-align: top ;"> Wednesday 23 April 2025 </td></tr><tr><td style="width:321px;;vertical-align: top ;"> Half-Year Financial Report January-June 2025 </td><td style="width:321px;;vertical-align: top ;"> Friday 18 July 2025 </td></tr><tr><td style="width:321px;;vertical-align: top ;"> Interim Report January-September 2025 </td><td style="width:321px;;vertical-align: top ;"> Tuesday 28 October 2025 </td></tr></tbody></table> The Financial Statements and the Report of the Board of Directors for 2024 will be published on the Company's website at the latest in week 11/2025. The Annual General Meeting is planned to be held on Thursday, 3 April 2025. Orion's financial reports and related presentation material are available on the Group's website at http://www.orion.fi/investors promptly after the publishing. The website also provides a possibility to register on Orion's mailing lists for releases.&nbsp; Orion Corporation <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tbody><tr><td style="width:18.52%;;vertical-align: top ;"> Liisa Hurme President and CEO </td><td style="width:3.24%;;vertical-align: top ;"> &nbsp;&nbsp;&nbsp; </td><td style="width:18.52%;;vertical-align: top ;"> Olli Huotari SVP, Corporate Functions </td><td style="width:9.72%;;vertical-align: top ;"> &nbsp; </td></tr></tbody></table> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contact person: Tuukka Hirvonen, Investor Relations tel. +358 10&nbsp;426 2721 Publisher: Orion Corporation Communications Orionintie 1A, FI-02200 Espoo, Finland <a href="https://www.globenewswire.com/Tracker?data=JTNPNeBNTczR45L-KV9_4WNYbHHoiOKUOymHCQ3jsPkgJlkBU2N7PdLoWmPOpyhbUuB1uy9HY2-9ws4AxrRk1YsmSN1-avwJkSztfJRwWeY=">http://www.orion.fi/en</a> <a href="https://www.globenewswire.com/Tracker?data=JTNPNeBNTczR45L-KV9_4TemWVNg8H4gXhcCRehJXwI7thImrGzZRYM2vs_upjvykiMHjaTqfosWgHvkiBV29KU36zhY6tTT4jsx1Tyu4ZyMiqnS9_Pdwx-vvAlTpkq0">http://www.twitter.com/OrionCorpIR</a> Orion is a globally operating Finnish pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&amp;D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2023 amounted to EUR 1,190 million and the company had about 3,600 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki. <img src="https://www.globenewswire.com/newsroom/ti?nf=MTAwMDk4NTU0NSM0MDE5MTY1NzQjMjAwMTk2Mw=="> <img src="https://ml-eu.globenewswire.com/media/OTI0YzQxN2QtNWM3Ny00MzkyLWJhYjUtYzI4M2VlYjExMWIwLTEwMTM1MzY=/tiny/Orion-Oyj.png">

Interim Report January-March 2025	Wednesday 23 April 2025
Half-Year Financial Report January-June 2025	Friday 18 July 2025
Interim Report January-September 2025	Tuesday 28 October 2025